Harwin Peter Evan 4
4 · Cogent Biosciences, Inc. · Filed Jun 13, 2024
Insider Transaction Report
Form 4
Harwin Peter Evan
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-06-05+44,700→ 44,700 totalExercise: $8.92Exp: 2034-06-05→ Common Stock (44,700 underlying)
Footnotes (2)
- [F1]This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders.
- [F2]Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.